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Abstract
OBJECTIVE—To identify factors associated with continuity of care and human 
immunodeficiency virus (HIV) virologic suppression among postpartum women diagnosed with 
HIV during pregnancy in New York State.
METHODS—This retrospective cohort study was conducted among 228 HIV-infected women 
diagnosed during pregnancy between 2008 and 2010. Initial receipt of HIV-related medical care 
(first CD4 or viral load test after diagnosis) was evaluated at 30 days after diagnosis and before 
delivery. Retention in care (2 or more CD4 or viral load tests, 90 days or greater apart) and 
virologic suppression (viral load 200 copies/mL or less) were evaluated in the 12 months after 
hospital discharge.
RESULTS—Most women had their initial HIV-related care encounter within 30 days of diagnosis 
(74%) and before delivery (87%). Of these women, 70% were retained in the first year postpartum. 
Women waiting more than 30 days for their initial HIV-related care encounter were more likely 
diagnosed in the first (29%) compared with the third (11%) trimester and were of younger 
(younger than 25 years, 32%) compared with older (35 years or older, 13%) age. Loss to follow-up 
within the first year was significantly greater among women diagnosed in the third compared with 
the first trimester (adjusted relative risk 2.21, 95% confidence interval [CI] 1.41–3.45) and among 
women who had a cesarean compared with vaginal delivery (adjusted relative risk 1.76, 95% CI 
1.07– 2.91). Of the 178 women with one or more HIV viral load test in the first year postpartum, 
58% had an unsuppressed viral load.
CONCLUSION—Despite the high proportion retained in care, many women had poor postpartum 
virologic control. Robust strategies are needed to increase virologic suppression among newly 
diagnosed postpartum HIV-infected women.
An estimated 200,000 women in the United States are infected with human 
immunodeficiency virus (HIV),1 of whom a small fraction deliver a neonate each year.2 
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Considerable public health resources have been used to raise awareness among women at 
high risk for HIV infection as well as provide information for those already infected about 
ways to reduce transmission to the neonate. As a result, mother-to-child transmission of HIV 
in the United States is uncommon.3 In New York state, nearly all pregnant women are aware 
of their HIV status before delivery and prophylaxis is provided to exposed neonates 
identified through maternal or newborn testing.4,5 The result has been the near elimination 
of mother-to-child transmission in New York state; only two cases of perinatally acquired 
HIV were reported in 2013. However, approximately 400 HIV-positive women deliver every 
year and are in need of postpartum HIV care.
Human immunodeficiency virus–positive women are more likely to adhere to treatment 
during pregnancy than after.6 Prior studies report that only approximately one third of 
women engage in postpartum HIV-related care,7–9 increasing the likelihood of poor 
virologic control postpartum.9 Few studies have evaluated HIV care and outcomes during 
the postpartum period among women in the United States; none has specifically focused on 
women diagnosed during pregnancy. The HIV care outcomes for this group may differ from 
women diagnosed before pregnancy. The primary objective of this study was to describe 
initial receipt of HIV-related care and postpartum retention in HIV-related care among 
women diagnosed with HIV during pregnancy. We also evaluated HIV viral suppression in 
the first year postpartum.
MATERIALS AND METHODS
This retrospective cohort study was conducted among newly diagnosed HIV-infected women 
with a live birth, who were eligible for inclusion in the study if they: 1) gave birth to a live 
neonate from 2008 to 2010, 2) were diagnosed with HIV infection while pregnant, 3) were 
reported to the New York State HIV Surveillance Registry, 4) resided in New York state at 
HIV diagnosis, 5) had a residence at diagnosis that could be geo-located, and 6) had a 
recorded discharge date.
The New York State Department of Health’s Surveillance Registry receives name-based 
reports for all HIV-related laboratory test results (eg, CD4 counts and percent, viral load 
tests, nucleotide sequences from genotype resistance testing) for individuals who reside or 
receive HIV-related care in the state.10 The Surveillance Registry routinely undergoes 
quality control and verification in conformity with the Centers for Disease Control and 
Prevention’s HIV Surveillance Guidelines.11 Human immunodeficiency virus medical visits 
were approximated using recorded CD4 and viral load laboratory tests12 assessed for the 12 
months after hospital discharge. Laboratory data from January 2008 to December 2011 were 
used to equalize the observation period for all study participants. This study was approved 
by the New York State Department of Health institutional review board. Because the study 
used data reported to the HIV Surveillance Registry and there was no contact with infected 
persons, informed consent was not required.
Human immunodeficiency virus–infected women who delivered a live neonate were 
identified by linking case records from the New York State HIV Perinatal Database to the 
statewide HIV Surveillance Registry. All neonates born in New York state are screened for 
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HIV antibodies. Neonates are identified in the Perinatal Database based on a positive HIV 
antibody result. Additional case data are obtained from diagnostic laboratory testing of 
exposed neonates and abstraction from the prenatal, labor and delivery, newborn, and 
pediatric medical records. Only mothers with an existing case record in the Statewide HIV 
Registry could be studied. New York state laws prohibit the creation of a case record for 
mothers who have not themselves consented to be tested for HIV; only one occurrence was 
recorded between 2008 and 2010.
Women were categorized as diagnosed with HIV during pregnancy based on reports to the 
Perinatal Database. Timing of diagnosis was validated by estimating the start of pregnancy 
(ie, the neonate’s birth date minus gestational age at delivery) and then comparing this date 
with the date of diagnosis reported to the HIV Surveillance Registry. Women diagnosed 
between admission for delivery and up to 14 days after delivery were categorized as 
diagnosed at delivery. Demographic data and clinical outcomes were obtained from the New 
York State HIV Surveillance Registry. Pregnancy-related variables such as type of delivery, 
neonate’s birth date, and gestational age at delivery were obtained from the Perinatal 
Database.
The three HIV care-related outcomes evaluated in this study were: 1) initial receipt of HIV-
related care, 2) retention in care in the first year postpartum, and 3) virologic suppression in 
the first year postpartum. Initial receipt of HIV-related care was assessed as occurring within 
30 days after diagnosis or longer based on the time between the date of diagnosis and the 
date of the first laboratory test (ie, CD4 or HIV viral load test) reported to the Surveillance 
Registry. Initial receipt of HIV-related care also was assessed as occurring before or after 
delivery. Retention in HIV care was defined as two or more laboratory tests (ie, CD4 or viral 
load tests) in the 12 months after delivery hospital discharge separated by at least 90 days.13 
Human immunodeficiency virus virologic suppression was defined as a quantitative viral 
load test 200 copies/mL or less. Women were categorized as virologically suppressed if all 
reported viral loads were 200 copies/mL or less during the first postpartum year.
Bivariate analyses using unadjusted relative risks (RRs) with 95% confidence intervals (CIs) 
were conducted to test associations between categorical study variables and outcomes. 
Stratified analyses were used to evaluate the interaction of study variables with each other 
and the study outcomes. Women who met the study inclusion criteria were included in the 
analysis of initial receipt of HIV-related care and postpartum HIV viral suppression, but only 
those women whose initial care encounter occurred before delivery were evaluated in the 
analysis of retention in care.
Missing values were imputed for number of previous live births (18%), last viral load before 
delivery (15%), low birth weight, and percent residing in a high-poverty area (less than 1% 
each) using Sequential Regression Multivariate Imputation14 implemented using IVEware.15 
Separate models were fitted for retention and virologic suppression using Poisson 
regression16,17 solved using generalized estimating equations.18 Only covariates that best 
predicted (P<.05) each outcome were retained in the final models. Multivariable associations 
were reported as adjusted RRs with 95% CIs. Because the standard analysis approach is to 
model the less frequent outcome, the RRs of not initiating HIV care, and not being retained 
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in care (ie, lost to follow-up in the first year postpartum) are presented. Data analyses were 
conducted using SAS 9.3 and IVEware.15
RESULTS
Between 2008 and 2010, 254 women with a live birth in New York state were identified as 
having been diagnosed with HIV during pregnancy. Women were excluded if they: 1) had a 
missing maternal discharge date (n=15), 2) resided outside of New York state at HIV 
diagnosis (n=4), or 3) had insufficient address information to geo-locate residence at 
delivery (n=7). An additional 30 women who did not receive HIV-related care before 
delivery were excluded from the analysis of retention in care.
Of the 30 women whose initial receipt of HIV-related care occurred after delivery, two, five, 
and seven women were diagnosed in the first, second, and third trimesters, respectively; 16 
were diagnosed at delivery. Women whose initial receipt of HIV-related care occurred after 
delivery were predominately black (60%) or Hispanic (27%) and aged younger than 25 years 
(40%). Seven had no reported viral load test in the 12 months after delivery and the 
remaining women (n=23) had an unsuppressed viral load at the first test in the 12-month 
postpartum follow-up period.
Women in the study were predominately black (61%) (Table 1). The median age at HIV 
diagnosis was 27.5 years (range 15.0–45.0 years). Almost two thirds (64%) resided in 
census tracts where more than 20% lived below the federal poverty level. Most women were 
diagnosed with HIV in the first (46%) or second (30%) trimesters of pregnancy. The 
majority (94%) had documentation in the medical chart of at least one prenatal care visit. 
The date of prenatal care initiation was available for most women (77%); the majority of 
women had their HIV infection diagnosed in the trimester during which they initiated 
prenatal care (52% in the first trimester, 71% second, and 75% third). Five instances of 
mother-to-child transmission occurred, one each among women diagnosed in the first, 
second, and third trimesters and two among women diagnosed at delivery.
The majority (74%) of women had an initial HIV-related care encounter within 30 days of 
HIV diagnosis and 87% initiated care before delivery (Table 1). The median time to initial 
receipt of HIV-related care was 17 days (interquartile range 9–31 days). Although 
counterintuitive, for mathematical reasons, we modeled the likelihood of not having an 
initial HIV-related care encounter. Women who initiated HIV care more than 30 days after 
diagnosis appeared to have less urgent HIV treatment need. Fewer were simultaneously 
diagnosed with acquired immunodeficiency syndrome (4% compared with 29% of those 
with earlier care initiation [RR 0.14, 95% CI 0.02–0.95]). More were diagnosed in the first 
(29%) compared with the third (11%) trimester (RR 0.37, 95% CI 0.14–0.98). Additionally, 
younger (younger than 25 years) women were more likely to begin care more than 30 days 
after diagnosis as compared with older (35 years) women (32% compared with 13%, 
respectively, RR 2.54, 95% CI 1.05–6.11).
Women who did not initiate HIV-related care before delivery were more likely to have 
injection drug use as the HIV transmission risk compared with other women (60% compared 
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with 11%, respectively, RR 5.45, 95% CI 2.90–10.25) and initiated prenatal care in the third 
compared with first-trimester care (18% compared with 2%, respectively, RR 9.67, 95% CI 
2.10–44.53).
The neonate’s health was significantly associated with the mother’s receipt of HIV-related 
care before delivery. A total of 42 neonates had a low birth weight, and five were infected 
with HIV. Women who did not initiate HIV-related care before delivery were more likely to 
have a low-birth-weight neonate than women who did obtain HIV care before delivery (33% 
compared with 16%, RR 2.04, 95% CI 1.12–3.71). Although not statistically significant as a 
result of the small number of infected neonates, women who did not initiate HIV-related care 
before delivery were more likely to have a neonate infected with HIV (8% [2/26]) compared 
with women who initiated HIV-related care before delivery (2% [3/183]). Neither the 
neonate’s weight nor HIV infection status was associated with the mother’s retention in HIV 
care postpartum.
Of the 198 women who initiated HIV-related care before delivery, 70% were retained in the 
first year postpartum (Table 2). In multivariable analysis, trimester of diagnosis, type of 
delivery, and race were associated with loss to follow-up with a higher risk seen among 
women diagnosed in the third compared with the first trimester (adjusted RR 2.21, 95% CI 
1.41–3.45), cesarean delivery compared with vaginal delivery (adjusted RR 1.76, 95% CI 
1.07–2.91), and white compared with black race (adjusted RR 1.91, 95% CI 1.08–3.40). 
Having an unsuppressed viral load at delivery (RR 1.90, 95% CI 1.25–2.91) was associated 
with an increased risk of loss to follow-up in bivariate but not multivariable analysis. The 
final model included no variables with imputed data. Trimester of HIV diagnosis appeared to 
modify the association between viral load at delivery and loss to follow-up in stratified 
analyses; however, sparse data prevented evaluation of this interaction in multivariable 
analysis. One woman who initiated HIV-related care before delivery died in the first year 
postpartum.
A total of 228 women were evaluated for HIV viral suppression. There was a median of two 
viral load tests in the first year postpartum (interquartile range 1–3 tests) and the median 
time between discharge and first viral load test was 71 days (interquartile range 40–122 
days). Approximately one in five women (22% [n=50]) had no viral load test reported to the 
surveillance registry in the first year postpartum and 17% (n=38) had only one test. The 50 
women with no viral load test were notable for the proportion with a CD4 report (40%); 
median cell counts ranged from 121 to 939 cells/mm3. Among the 178 women with one or 
more viral load tests, 42% (n=74) were suppressed on every test in the first year postpartum 
(not shown). There were 144 women (77%) who initiated HIV-related care before delivery 
and were virally suppressed at the last test before delivery (Table 2); 16% (n=23) had no 
reported viral load test in the first year postpartum. Of the remaining 121 women, 52% had 
one or more viral load tests greater than 200 copies/mL. The majority (67%) were virally 
suppressed at the first viral load test in the first year postpartum and the first postpartum 
viral load test exceeded 1,000 copies/ mL for 24% (n=29); time between discharge and first 
viral load test postpartum was 66 days (interquartile range 41–101 days).
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The majority of women diagnosed with HIV during pregnancy in the present study initiated 
HIV-related care before delivery (87%), and among those women, 70% were retained in care 
during the first year postpartum. The high frequency of initiating HIV-related care during 
pregnancy and postpartum retention in HIV-related care observed is likely attributable, in 
part, to New York’s robust public health policy and infrastructure, including HIV case 
management, outreach for early prenatal care, and medical coverage for infected persons 
with medication assistance for uninsured or underinsured individuals.4,19 However, more 
than half (58%) of women with a postpartum HIV viral load test did not achieve virologic 
suppression. Newly diagnosed women appear to merit special attention during the first year 
postpartum.
The observed proportion of women retained in care in New York state was nearly twice that 
reported by similar previous studies.7–9 However, prior clinic-based investigations did not 
track patient care outside specific facilities, which may have resulted in an underestimate of 
retention in care. In contrast to previous work,7 white race was associated with loss to 
follow-up and no association with age was observed, likely as a result of differences in 
patient care settings.7
In New York state, HIV screening has been achieved in 95% of pregnant women.4 Diagnosis 
later in pregnancy was associated with a higher likelihood of loss to follow-up, a finding 
consistent with previous studies.7,8 In addition to aggressive follow-up of women diagnosed 
later in pregnancy, there is precedent for antepartum interventions, administered as an 
adjunct to standard prenatal care, that promote behavior change. For example, a study of 
screening for diabetes mellitus among women with gestational diabetes reported a 
significant increase in testing in the 6 months after delivery among women who received an 
educational intervention.20 Care coordination among those with HIV has resulted in better 
engagement in care, better HIV viral suppression, and improved immune function.21,22 
Coupling behavior change models with care coordination may be a powerful tool to improve 
care outcomes among postpartum women.
The management of a new HIV diagnosis among women already struggling to access and 
sustain health care suggests the need for intensive care coordination efforts. Although 
potentially resource-intensive,22 public health programs have demonstrated success in 
meeting the needs of high-risk individuals.21 Women diagnosed with HIV during pregnancy 
represent a small number of total deliveries each year. However, many will have additional 
children. Maintaining HIV virologic control can improve future pregnancy-related outcomes 
and decrease adverse HIV-related diseases outcomes. A partnership among obstetricians and 
gynecologists, internal medicine, and public health professionals could facilitate care 
transition and prevent declines in health status. Research is needed to understand the specific 
barriers to care associated with the first year postpartum and inform the development of care 
coordination interventions.
New York has reduced mother-to-child transmission through programs that promote 
virologic control before delivery4 and through fully funding health care and medication for 
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at-risk and infected women who are living in poverty.23 Although 75% of women were 
virally suppressed at delivery, half of those who could be followed were not suppressed in 
the first year postpartum and 24% rebounded to a viral load level of more than 1,000 
copies/mL by the first test postpartum. Effective interventions must offset competing 
demands, for example, caregiver responsibilities,24 that prevent postpartum HIV-infected 
women from maintaining the virologic suppression achieved during pregnancy.
This population-based study utilized HIV laboratory data from the New York State HIV 
Surveillance Registry with birth information from the New York State HIV Perinatal 
Database. Our assessment of HIV care outcomes therefore captured encounters with medical 
care providers even if these encounters occurred at multiple facilities, a limitation of 
previous clinic-based studies.7,8 The use of CD4 count and viral load laboratory tests as 
proxy measures for HIV medical care may limit our ability to evaluate postpartum retention 
in care and HIV viral suppression because we did not capture medical visits unless a test 
was ordered. Alternatively, CD4 and viral load tests may overestimate care if they are 
conducted in the absence of a medical visit. Finally, our findings for retention in care may be 
conservative because some women who were not retained may be in care outside New York 
state.
This analysis extends previous research by evaluating initial receipt of HIV-related care, 
postpartum retention in care, and HIV viral suppression among women diagnosed during 
pregnancy, a relatively understudied area of HIV-infected U.S. women. Treatment guidelines 
recommend systematic monitoring of HIV-infected women in the postpartum period with 
adherence and retention support for women during this time.25,26 Despite the high 
proportion retained, many women had poor virologic control in the first year postpartum. 
These findings highlight subgroups of postpartum women who are particularly susceptible to 
adverse HIV care outcomes and underscore the need for increased support to enhance 
adherence in the postpartum period for women with newly diagnosed HIV infection.
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Table 1
Factors Associated With Initial Receipt of Human Immunodeficiency Virus–Related Care* Among Women 
With a Live Birth Who Were Diagnosed With Human Immunodeficiency Virus Infection During Pregnancy
Initial Care Within 30 D of Diagnosis
Characteristic Total (N=228) Yes (n=168 [74]) No (n=60 [26]) RR (95% CI)†
Race–ethnicity
  Black 139 (61) 99 (71) 40 (29) Referent
  White 15 (7) 13 (87) 2 (13) 0.46 (0.12–1.73)
  Hispanic 59 (26) 45 (76) 14 (24) 0.82 (0.49–1.40)
  Other or unknown 15 (7) 11 (73) 4 (27) 0.93 (0.38–2.23)
Age at HIV diagnosis (y)
  Younger than 25 82 (36) 56 (68) 26 (32) 2.54 (1.05–6.11)‡
  25–29 61 (27) 45 (74) 16 (26) 2.10 (0.83–5.27)
  30–34 45 (20) 32 (71) 13 (29) 2.31 (0.90–5.91)
  35 or older 40 (18) 35 (88) 5 (13) Referent
% below poverty§
  Less than 20 81 (36) 59 (73) 22 (27) 0.79 (0.47–1.31)
  20 to less than 40 91 (40) 72 (79) 19 (21) 0.60 (0.35–1.04)
  40 or greater 55 (24) 36 (65) 19 (35) Referent
  Missing or unknown 1 (—) 1 (—) 0
HIV transmission risk
  Heterosexual 218 (96) 160 (73) 58 (27) Referent
  IDU 10 (4) 8 (80) 2 (20) 0.75 (0.21–2.65)
Concurrent HIV and AIDS diagnosis
  No 203 (89) 144 (71) 59 (29) Referent
  Yes 25 (11) 24 (96) 1 (4) 0.14 (0.02–0.95)‡
Trimester of HIV diagnosis
  1st 105 (46) 75 (71) 30 (29) Referent
  2nd 69 (30) 50 (72) 19 (28) 0.96 (0.59–1.57)
  3rd 38 (17) 34 (89) 4 (11) 0.37 (0.14–0.98)‡
  At delivery 16 (7) 9 (56) 7 (44) 1.53 (0.81–2.88)
Type of delivery
  Vaginal 96 (42) 70 (73) 26 (27) Referent
  Cesarean 132 (58) 98 (74) 34 (26) 0.95 (0.61–1.47)
No. of previous live births
  0 78 (42) 56 (72) 22 (28) 1.29 (0.72–2.31)
  1 44 (24) 30 (68) 14 (32) 1.45 (0.77–2.74)
  2 or more 64 (34) 50 (78) 14 (22) Referent
Unknown 42 (—) 32 (—) 10 (—)
Low-birth-weight neonate
  Yes 42 (19) 28 (67) 14 (33) 1.36 (0.83–2.24)
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Initial Care Within 30 D of Diagnosis
Characteristic Total (N=228) Yes (n=168 [74]) No (n=60 [26]) RR (95% CI)†
  No 184 (81) 139 (76) 45 (24) Referent
  Unknown 2 (—) 1 (—) 1 (—)
Neonate’s HIV infection status
  Infected 5 (2) 4 (80) 1 (20) 0.74 (0.13–4.34)
  Uninfected 204 (98) 149 (73) 55 (27) Referent
  Unknown 19 (—) 15 (—) 4 (—)
Initial Care Before Delivery
Yes (n=198 [87]) No (n=30 [13]) RR (95% CI)†
121 (87) 18 (13) Referent
12 (80) 3 (20) 1.54 (0.51–4.64)
51 (86) 8 (14) 1.05 (0.48–2.27)
14 (93) 1 (7) 0.51 (0.07–3.59)
70 (85) 12 (15) 0.84 (0.36–1.96)
56 (92) 5 (8) 0.47 (0.16–1.37)
39 (87) 6 (13) 0.76 (0.28–2.08)
33 (83) 7 (18) Referent
73 (90) 8 (10) 0.60 (0.25–1.47)
78 (86) 13 (14) 0.87 (0.40–1.91)
46 (84) 9 (16) Referent
1 (—) 0
194 (89) 24 (11) Referent
4 (40) 6 (60) 5.45 (2.90–10.25)‡
175 (86) 28 (14) Referent
23 (92) 2 (8) 0.58 (0.15–2.29)
103 (98) 2 (2) Referent
64 (93) 5 (7) 3.80 (0.76–19.06)
31 (82) 7 (18) 9.67 (2.10–44.53)‡
NA 16 (100) NA
81 (84) 15 (16) Referent
117 (89) 15 (11) 0.73 (0.37–1.42)
78 (100) 0 NA
40 (91) 4 (9) 0.73 (0.23–2.27)
56 (88) 8 (13) Referent
24 (—) 18 (—)
32 (76) 10 (24) 2.19 (1.11–4.33)‡
164 (89) 20 (11) Referent
2 (—) 0
3 (60) 2 (40) 3.40 (1.09–10.60)‡
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180 (88) 24 (12) Referent
15 (—) 4 (—)
RR, relative risk; CI, confidence interval; HIV, human immunodeficiency virus; IDU, intravenous drug user; AIDS, acquired immunodeficiency 
syndrome; NA, not applicable.
Data are n (%) unless otherwise specified.
*
Initial receipt of HIV-related care is after diagnosis.
†
RR of not initiating care compared with referent.
‡
Statistically significant RR, 95% CI does not include 1.
§
Percentage of persons living below poverty in the census tract of mother’s residence at delivery.













Swain et al. Page 13
Table 2
Loss to Follow-up in the First Year Postpartum Among Human Immunodeficiency Virus–Infected Women 





(95% CI)*†Yes (n=60) No (n=138 [70])
Race–ethnicity
  Black 121 (61) 38 (31) 83 (69) Referent Referent
  White 12 (6) 6 (50) 6 (50) 1.59 (0.85–2.97) 1.91 (1.08–3.40)‡
  Hispanic 51 (26) 11 (22) 40 (78) 0.69 (0.38–1.23) 0.79 (0.44–1.40)
  Other or unknown 14 (7) 5 (36) 9 (64) 1.14 (0.54–2.41) 1.22 (0.59–2.54)
HIV transmission risk
  Heterosexual 194 (98) 60 (31) 134 (69) Referent NA
  IDU 4 (—) 0 4 (100) NA NA
Concurrent HIV and AIDS diagnosis
  No 175 (88) 56 (32) 119 (68) Referent Referent
  Yes 23 (12) 4 (17) 19 (83) 0.54 (0.22–1.36) 0.45 (0.20–1.00)
Trimester of HIV diagnosis
  1st 103 (52) 26 (25) 77 (75) Referent Referent
  2nd 64 (32) 17 (27) 47 (73) 1.05 (0.62–1.78) 1.05 (0.62–1.77)
  3rd 31 (16) 17 (55) 14 (45) 2.17 (1.37–3.44)‡ 2.21 (1.41–3.45)‡
Delivery type
  Vaginal 81 (41) 16 (20) 65 (80) Referent Referent
  Cesarean 117 (59) 44 (38) 73 (62) 1.90 (1.16–3.13)‡ 1.76 (1.07–2.91)‡
CD4 count/mm3 at delivery§
  0–350 47 (24) 13 (28) 34 (72) 0.89 (0.53–1.49) NA
  350 or more 151 (76) 47 (31) 104 (69) Referent NA
Viral load at delivery§
  Suppressed 144 (77) 36 (25) 108 (75) Referent NA
  Not suppressed 42 (23) 20 (48) 22 (52) 1.90 (1.25–2.91)‡ NA
  Missing or unknown 12 (—) 4 (—) 8 (—)
  Low-birth-weight neonate
    Yes 32 (16) 8 (25) 24 (75) 0.80 (0.42–1.53) NA
    No 164 (84) 51 (31) 113 (69) Referent NA
    Unknown 2 (—) 1 (—) 1 (—)
  Neonate’s HIV infection status
    Infected 3 (—) 0 3 (100) NA NA
    Uninfected 180 (98) 51 (28) 129 (72) Referent NA
    Unknown 15 (—) 9 (—) 6 (—)
RR, relative risk; CI, confidence interval; HIV, human immunodeficiency virus; IDU, intravenous drug user; AIDS, acquired immunodeficiency 
syndrome; NA, not applicable.
Data are n (%) unless otherwise specified.
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*
RR of being lost to follow-up compared with referent.
†
Parsimonious model shown. Variables considered in model selection were: residence at diagnosis, race–ethnicity, age at diagnosis, year of 
diagnosis, percent below poverty, concurrent HIV and AIDS diagnosis, trimester of diagnosis, delivery type, number of previous live births, viral 
load at delivery, low birth weight.
‡
Statistically significant RR, CI does not include 1.
§
Test closest to but preceding delivery.
Obstet Gynecol. Author manuscript; available in PMC 2017 August 15.
